Vascular malformations syndromes: an update.

PURPOSE OF REVIEW To provide an update of vascular malformation syndromes by reviewing the most recent articles on the topic and following the new International Society for the Study of Vascular Anomalies (ISSVA) 2018 classification. RECENT FINDINGS This review discusses the main features and diagnostic approaches of the vascular malformation syndromes, the new genetic findings and the new therapeutic strategies developed in recent months. SUMMARY Some vascular malformations can be associated with other anomalies, such as tissue overgrowth. PIK3CA-related overgrowth spectrum (PROS) is a group of rare genetic disorders with asymmetric overgrowth caused by somatic mosaic mutations in PI3K-AKT-mTOR pathway that encompass a heterogeneous group of rare disorder that are associated with the appearance of overgrowth. CLOVES syndrome and Klippel-Trénaunay syndrome are PROS disease. Proteus syndrome is an overgrowth syndrome caused by a somatic activating mutation in AKT1. CLOVES, Klippel-Trénaunay and Proteus syndromes are associated with high risk of thrombosis and pulmonary embolism. Hereditary hemorrhagic telangiectasia is an autosomic dominant disorder characterized by the presence of arteriovenous malformations. New therapeutic strategies with bevacizumab and thalidomide have been employed with promising results.

[1]  Yizhong Wang,et al.  Magnetically Controlled Capsule Endoscopy in Children: A Single-center, Retrospective Cohort Study. , 2019, Journal of pediatric gastroenterology and nutrition.

[2]  E. Barbi,et al.  Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature , 2019, Pediatric Drugs.

[3]  S. Blaise,et al.  Photoacoustic imaging as an innovative technique for the exploration of blue rubber bleb naevus , 2019, The British journal of dermatology.

[4]  Jun Yang,et al.  Endoglin is a conserved regulator of vasculogenesis in zebrafish – implications for hereditary haemorrhagic telangiectasia , 2019, Bioscience reports.

[5]  J. Teng,et al.  Successful treatment of spindle cell hemangiomas in a patient with Maffucci syndrome and review of literatures , 2019, Dermatologic therapy.

[6]  B. Khaitan,et al.  Unsatisfactory response to sirolimus in Maffucci syndrome‐associated spindle cell hemangiomas , 2019, Dermatologic therapy.

[7]  A. Nordgren,et al.  Early activating somatic PIK3CA mutations promote ectopic muscle development and upper limb overgrowth , 2019, Clinical genetics.

[8]  O. Gerke,et al.  Long-Term Single-Center Retrospective Follow-Up After Embolization of Pulmonary Arteriovenous Malformations Treated Over a 20-year Period: Frequency of Re-canalization with Various Embolization Materials and Clinical Outcome , 2019, CardioVascular and Interventional Radiology.

[9]  C. Shovlin,et al.  Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia , 2019, Orphanet Journal of Rare Diseases.

[10]  P. Ewings,et al.  Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol , 2019, BMJ Open.

[11]  T. Matsumoto,et al.  Gastrointestinal: Endoscopic injection sclerotherapy for duodenal vascular malformation in blue rubber bleb nevus syndrome , 2019, Journal of gastroenterology and hepatology.

[12]  J. Kjeldsen,et al.  Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. , 2019, Rhinology.

[13]  P. Lapunzina,et al.  Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly , 2018, The Journal of experimental medicine.

[14]  Brian A Palmer,et al.  Pain, psychiatric comorbidities, and psychosocial stressors associated with Klippel‐Trenaunay syndrome , 2018, Journal of the American Academy of Dermatology.

[15]  Maneesh C. Patel,et al.  Uptake and radiological findings of screening cerebral magnetic resonance scans in patients with hereditary haemorrhagic telangiectasia. , 2018, Intractable & rare diseases research.

[16]  Julie C. Sapp,et al.  Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum , 2018, Genetics in Medicine.

[17]  Osamah Alwalid,et al.  Radiological Aspect of Klippel-Trénaunay Syndrome: A Case Series With Review of Literature , 2018, Current Medical Science.

[18]  Ralitsa R. Madsen,et al.  Cancer-Associated PIK3CA Mutations in Overgrowth Disorders , 2018, Trends in molecular medicine.

[19]  P. Jervis,et al.  The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. , 2018, The Journal of laryngology and otology.

[20]  G. Chaudry,et al.  Pulmonary thromboembolic events in patients with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal/skeletal abnormalities and Klippel-Trénaunay syndrome. , 2018, Journal of vascular surgery. Venous and lymphatic disorders.

[21]  Laureline Berteloot,et al.  Targeted therapy in patients with PIK3CA-related overgrowth syndrome , 2018, Nature.

[22]  P. Sutphin,et al.  Pulmonary arteriovenous malformations: diagnosis. , 2018, Cardiovascular diagnosis and therapy.

[23]  J. Rimmer,et al.  Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review. , 2018, Rhinology.

[24]  A. Mansilha,et al.  Vascular malformations: classification, diagnosis and treatment. , 2018, International angiology : a journal of the International Union of Angiology.

[25]  J. Clayton-Smith,et al.  Hypoglycaemia represents a clinically significant manifestation of PIK3CA‐ and CCND2‐associated segmental overgrowth , 2018, Clinical genetics.

[26]  D. Zurakowski,et al.  Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA‐related overgrowth spectrum , 2018, Clinical genetics.

[27]  J. Mulliken,et al.  A cross‐sectional survey of long‐term outcomes for patients with diffuse capillary malformation with overgrowth , 2017, Journal of the American Academy of Dermatology.

[28]  L. Biesecker,et al.  Pathogenetic insights from quantification of the cerebriform connective tissue nevus in Proteus syndrome , 2017, Journal of the American Academy of Dermatology.

[29]  C. Shields,et al.  CHOROIDAL MELANOMA IN PHAKOMATOSIS PIGMENTOVASCULARIS WITH KLIPPEL–TRENAUNAY SYNDROME , 2017, Retina.

[30]  M. Mackay,et al.  Screening for Sturge‐Weber syndrome: A state‐of‐the‐art review , 2018, Pediatric dermatology.

[31]  S. Middeldorp,et al.  Complications of pregnancy and labour in women with Klippel–Trénaunay syndrome: a nationwide cross‐sectional study , 2017, BJOG : an international journal of obstetrics and gynaecology.

[32]  A. D. Rodríguez,et al.  Análisis del síndrome de Sturge-Weber: estudio retrospectivo de múltiples variables asociadas , 2017 .

[33]  Marilyn M. Li,et al.  Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel. , 2017, The Journal of molecular diagnostics : JMD.

[34]  Z. Rancic,et al.  Parkes Weber syndrome—Diagnostic and management paradigms: A systematic review , 2017, Phlebology.

[35]  M. Dalsing,et al.  Diagnosis and management of the venous malformations of Klippel-Trénaunay syndrome. , 2017, Journal of vascular surgery. Venous and lymphatic disorders.

[36]  Julie C. Sapp,et al.  Characterization of thrombosis in patients with Proteus syndrome , 2017, American journal of medical genetics. Part A.

[37]  J. Mulliken,et al.  Sonographic screening for Wilms tumor in children with CLOVES syndrome , 2017, Pediatric blood & cancer.

[38]  Julie C. Sapp,et al.  Quantifying survival in Patients with Proteus Syndrome , 2017, Genetics in Medicine.

[39]  C. Kin,et al.  Say What? Bannayan–Riley–Ruvalcaba Syndrome Presenting with Gastrointestinal Bleeding Due to Hamartoma-Induced Intussusception , 2017, Digestive Diseases and Sciences.

[40]  M. H. Ali,et al.  Pathophysiology, diagnosis, and management of glaucoma associated with Sturge–Weber syndrome , 2017, International Ophthalmology.

[41]  C. Eng,et al.  Breast cancer risk and clinical implications for germline PTEN mutation carriers , 2017, Breast Cancer Research and Treatment.

[42]  R. Weksberg,et al.  Molecular Mechanisms of Childhood Overgrowth , 2013, American journal of medical genetics. Part C, Seminars in medical genetics.

[43]  J. Glowacki,et al.  Hemangiomas and Vascular Malformations in Infants and Children: A Classification Based on Endothelial Characteristics , 1982, Plastic and reconstructive surgery.